Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H8O3 |
Molecular Weight | 152.1473 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(O)C=CC=C1
InChI
InChIKey=OSWPMRLSEDHDFF-UHFFFAOYSA-N
InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3
Molecular Formula | C8H8O3 |
Molecular Weight | 152.1473 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdfCurator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Sources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.
Originator
Sources: http://www.casinapioiv.va/content/dam/accademia/pdf/acta18/acta18-szczeklik.pdfhttps://books.google.ru/books?id=iUpwBAAAQBAJ&pg=PT83&lpg=PT83&dq=Methyl+salicylate+Auguste+Andr%C3%A9+Thomas+Cahours&source=bl&ots=nFDf2n2bpT&sig=wAKTDamdc7xWWgRxOrTeokeji8g&hl=ru&sa=X&ved=0ahUKEwj-q8769PzTAhVFfhoKHYEqDgkQ6AEIODAD#v=onepage&q=Methyl%20salicylate%20Auguste%20Andr%C3%A9%20Thomas%20Cahours&f=false
Curator's Comment: first isolated in 1843
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL2311236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26101955 |
1.48 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date1.35501119E12 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date1.35501119E12 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date1.35501119E12 |
Doses
Dose | Population | Adverse events |
---|---|---|
30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Other AEs: Redness, Scales... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Redness | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
|
Scales | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/9207195/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
major | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats. | 2001 |
|
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures. | 2001 |
|
Hydroxyl radical adduct of 5-aminosalicylic acid: a potential marker of ozone-induced oxidative stress. | 2001 |
|
Arabidopsis genome sequence as a tool for functional genomics in tomato. | 2001 |
|
[Principal constituents from flowering aerial parts of wild pansy]. | 2001 Apr |
|
A novel jasmonic acid-inducible rice myb gene associates with fungal infection and host cell death. | 2001 Apr |
|
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants. | 2001 Apr |
|
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane. | 2001 Apr |
|
Nucleotide sequence analysis of 5'-flanking region of salicylate hydroxylase gene, and identification and purification of a LysR-type regulator, SalR. | 2001 Apr |
|
Nitric oxide: comparative synthesis and signaling in animal and plant cells. | 2001 Apr |
|
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes. | 2001 Apr |
|
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. | 2001 Apr 17 |
|
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart. | 2001 Apr 30 |
|
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents]. | 2001 Apr 6 |
|
Hereditary palmoplantar keratoderma (four cases in three generations). | 2001 Feb |
|
Induction of wound response gene expression in tomato leaves by ionophores. | 2001 Feb |
|
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine. | 2001 Feb |
|
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance. | 2001 Feb |
|
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction. | 2001 Feb |
|
Ethylene-dependent salicylic acid regulates an expanded cell death response to a plant pathogen. | 2001 Feb |
|
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics. | 2001 Feb |
|
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells. | 2001 Jan |
|
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane. | 2001 Jan |
|
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate. | 2001 Jan |
|
Reversed-phase high-performance liquid chromatography versus spectrophotometric assay for thimerosal in Cuban recombinant hepatitis B vaccine. | 2001 Jan 12 |
|
Synthesis and metal binding properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized dendrimers. | 2001 Jan 5 |
|
Combined cryotherapy/70% salicylic acid treatment for plantar verrucae. | 2001 Jan-Feb |
|
Quantitative analysis of hydroxyl radicals in the anterior optic nerve of the cat following transient ischemia. | 2001 Jan-Feb |
|
Interaction of the Arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3. | 2001 Jul 13 |
|
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus. | 2001 Jul 6 |
|
A recessive mutation in the Arabidopsis SSI2 gene confers SA- and NPR1-independent expression of PR genes and resistance against bacterial and oomycete pathogens. | 2001 Mar |
|
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways. | 2001 Mar |
|
The Arabidopsis downy mildew resistance gene, RPP13-Nd, functions independently of NDR1 and EDS1 and does not require the accumulation of salicylic acid. | 2001 Mar |
|
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs. | 2001 Mar |
|
Identification of free radicals produced during phacoemulsification. | 2001 Mar |
|
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis. | 2001 Mar 1 |
|
Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. | 2001 Mar 15 |
|
Flow-through UV spectrophotometric sensor for determination of (acetyl)salicylic acid in pharmaceutical preparations. | 2001 Mar 23 |
|
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes. | 2001 Mar 23 |
|
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination. | 2001 Mar 30 |
|
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection. | 2001 Mar 5 |
|
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. | 2001 May |
|
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals. | 2001 May |
|
Acanthoamoeba attachment to contact lenses. | 2001 May |
|
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat. | 2001 May |
|
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein. | 2001 May |
|
Measurement of free radical production by in vivo microdialysis during ischemia/reperfusion injury to skeletal muscle. | 2001 May 1 |
|
Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen. | 2001 May 11 |
|
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. | 2001 May 8 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salicylic-acid.html
The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1811921
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:08:20 UTC 2023
by
admin
on
Fri Dec 15 15:08:20 UTC 2023
|
Record UNII |
LAV5U5022Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.544
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
||
|
CFR |
21 CFR 310.531
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
||
|
DSLD |
1268 (Number of products:9)
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
||
|
JECFA EVALUATION |
METHYL SALICYLATE
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LAV5U5022Y
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
4133
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
m7463
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | Merck Index | ||
|
8204
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
DB09543
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
68917-50-0
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
ALTERNATIVE | |||
|
68917-75-9
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
ALTERNATIVE | |||
|
SUB60752
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
31832
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
4245
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
119-36-8
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
C033069
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
100000084885
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
SUB15729MIG
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
LAV5U5022Y
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
C80564
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
1437450
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
1935
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
SUB14545MIG
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
DTXSID5025659
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
29787
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL108545
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
204-317-7
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
800
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY | |||
|
METHYL SALICYLATE
Created by
admin on Fri Dec 15 15:08:20 UTC 2023 , Edited by admin on Fri Dec 15 15:08:20 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
PARENT -> IMPURITY | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |